A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions

Healthy SubjectsAsthmatic Patients

Interventions

DRUG

SHR-4597

SHR-4597 by dry powder inhalation

DRUG

Placebo

Placebo by dry powder inhalation

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY